Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...

CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive ...

The study also demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...